STANFORD, CA – April 24, 2024 – In a discovery poised to revolutionize cancer immunotherapy, scientists have uncovered a surprising, critical role for a protein identified nearly four decades ago. Erythropoietin (EPO), long celebrated for its ability to stimulate red blood cell production, has now been revealed as a powerful orchestrator in dampening the immune system’s response to cancer, effectively cloaking tumors from attack. This groundbreaking research, published today in Science, illuminates a previously unrecognized mechanism of immune evasion and offers a compelling new target for cancer therapies.
The findings demonstrate that blocking EPO’s activity can transform notoriously "cold," or immune-resistant, liver tumors in mice into "hot" battlegrounds teeming with cancer-fighting immune cells. When this intervention was combined with an existing immunotherapy designed to further activate these immune cells, the results were dramatic: complete regression of existing liver tumors in the majority of treated animals, which subsequently lived for the entire duration of the experiment. In stark contrast, control animals succumbed to their disease within a matter of weeks.
"This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer," declared Dr. Edgar Engleman, MD, PhD, a professor of pathology and of medicine at Stanford University, and the senior author of the study. "I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials."
The lead author of the research is Dr. David Kung-Chun Chiu, PhD, a basic life research scientist whose innovative work in developing precise mouse models was instrumental to the discovery. While the initial investigations were conducted in murine models, strong indications suggest that EPO plays a strikingly similar immunosuppressive role across a spectrum of human cancers, paving the way for a paradigm shift in how we approach difficult-to-treat malignancies.
A Chronology of Discovery: From Red Blood Cells to Immune Evasion
The journey to understanding EPO’s dual nature has been long and circuitous, marked by decades of established knowledge and a recent, unexpected pivot. For much of its known history, EPO has been synonymous with erythropoiesis – the process of red blood cell formation. Identified in the 1970s, its primary physiological function in response to hypoxia (low oxygen levels) has been to stimulate the bone marrow to produce more red blood cells, thereby increasing oxygen delivery to tissues. This role has made synthetic EPO a vital therapeutic for patients suffering from anemia, particularly those with chronic kidney disease or undergoing chemotherapy.
The Ominous Link: EPO and Cancer Progression
However, an unsettling connection between EPO and cancer began to surface more than a decade ago. Clinical observations revealed a disturbing trend: giving EPO to anemic cancer patients to boost their red blood cell counts often led to an acceleration of tumor growth. This correlation was so pronounced and concerning that in 2007, the U.S. Food and Drug Administration (FDA) mandated a "black box warning" label on EPO-stimulating drugs, cautioning against their use in individuals with cancer.
Further research at the time also established a clear, albeit unexplained, link between patient prognosis and the natural levels of EPO and its receptor (EPOR) within the tumor microenvironment. "Those old reports showed clearly that the more EPO or EPOR there was in tumors, the worse off the patients were," Dr. Engleman recalled. Despite this compelling evidence, the precise mechanism behind EPO’s detrimental effect on cancer outcomes remained elusive. The scientific community, deeply ingrained with EPO’s role as a red blood cell growth factor, struggled to connect these observations to a broader biological function relevant to cancer pathology beyond simple growth stimulation. "But the connection between EPO and cancer immunity was never made until now. In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, because EPO is so well established as a red blood cell growth factor," Engleman explained.
Unraveling the Mystery: The Genesis of the Breakthrough
The true breakthrough began with Dr. Chiu’s meticulous work in developing sophisticated mouse models of liver cancer. Utilizing advanced genome editing techniques, Chiu engineered several distinct models that accurately recapitulated the specific mutations, histological features, and responses to approved therapies observed in various subtypes of human liver cancers. Tumor formation in these models was induced either by injecting DNA encoding proteins associated with liver cancer into the animals’ tail veins or by directly implanting liver cancer cells into the animals’ livers. This diversity in modeling was crucial for capturing the complexity and heterogeneity of human liver disease.
The researchers’ initial focus was on understanding the efficacy of a common immunotherapy targeting programmed cell death protein 1 (PD-1), a molecule found on immune cells called T cells. Anti-PD-1 therapies, such as the commercially available Keytruda, work by blocking PD-1, thereby preventing cancer cells from dampening the activity of T cells. These immunotherapies have transformed outcomes for patients with cancers like melanoma, Hodgkin’s lymphoma, and certain lung cancers. Yet, a significant majority of tumors – including most liver, pancreatic, colon, breast, and prostate cancers – remain stubbornly resistant to these treatments.
In their mouse models, the Stanford team observed patterns strikingly similar to those seen in human liver cancers. Some combinations of genetic mutations led to the development of "cold" tumors – immune-privileged entities largely ignored by the host immune system. These cold tumors contained few T cells and, consequently, showed no shrinkage when treated with anti-PD-1 therapy. Conversely, other mutations gave rise to "hot," or "inflamed," tumors. These tumors were replete with T cells and highly sensitive to anti-PD-1 treatment, which successfully triggered the T cells to launch a potent attack against the cancer.
The Unexpected Culprit: Hypoxia and EPO’s Immunosuppressive Role
The pivotal moment arrived with an unexpected observation: the cold, immune-resistant tumors displayed significantly elevated levels of EPO compared to their hot, immune-responsive counterparts. The researchers hypothesized that this increase was likely a direct consequence of the oxygen-poor microenvironment – a condition known as hypoxia – prevalent within cold tumors. Hypoxia is a common feature of rapidly growing tumors and is known to induce cancer cells to produce various proteins, including those that ramp up EPO production as a compensatory mechanism to stimulate more red blood cells and thus combat low oxygen levels.
"Hypoxia in tumors has been studied for decades," Dr. Engleman noted. "It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor." This realization marked a critical turning point, prompting the researchers to re-examine EPO’s role with a fresh perspective.
Curiosity piqued, the team delved into existing human cancer databases, confirming that elevated levels of EPO were indeed correlated with poorer survival rates in patients across various cancer types, including those of the liver, kidney, breast, colon, and skin. This strong correlative evidence in humans further bolstered the significance of their mouse model findings.
The definitive proof came from manipulating EPO production within the tumors themselves. The researchers genetically tinkered with the tumor cells’ ability to produce EPO, observing dramatic shifts in immune response. Mutations that had previously led to the development of cold tumors instead caused hot tumors when the tumors were modified to be incapable of making EPO. Conversely, hot tumors that had previously been successfully eradicated by the immune system thrived and became resistant to immune attack when they were engineered to produce elevated levels of EPO. These elegant experiments provided compelling, causal evidence for EPO’s direct role in shaping the tumor immune landscape.
The Mechanism Revealed: Macrophages as EPO’s Pawns
Further exhaustive research painstakingly elucidated the precise cellular and molecular mechanism at play. In cold tumors, cancer cells were found to produce and secrete EPO. This secreted EPO then binds to specific receptors (EPOR) located on the surface of nearby immune cells known as macrophages. Upon binding EPO, these macrophages undergo a critical transformation: they switch to an immunosuppressive role. In this altered state, macrophages actively "shoo away" cancer-killing T cells, preventing their infiltration into the tumor, and simultaneously tamp down any remaining T cell activity, effectively creating an immune-privileged sanctuary for the cancer.
The profound importance of this EPO-moderated crosstalk between tumor cells and macrophages was vividly demonstrated in experiments combining the blockade of the EPO signaling pathway with anti-PD-1 therapy. In these crucial experiments, mice with cold liver tumors treated either with a control substance or with anti-PD-1 alone survived no more than eight weeks after tumor induction. However, a striking 40% of mice whose macrophages were genetically engineered to be unable to make the EPO receptor lived for 18 weeks, the full duration of the experiment. The most remarkable outcome occurred when anti-PD-1 treatment was administered to mice lacking the EPO receptor on their macrophages: every single animal lived for the entire experimental period, demonstrating complete and sustained tumor regression.
"It’s simple," Dr. Engleman stated succinctly. "If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment." This clarity underscores the power of targeting this newly identified pathway.
Supporting Data and Scientific Rigor
The robustness of this discovery is underpinned by several key factors and meticulous experimental design. Dr. Chiu’s development of diverse liver cancer mouse models was critical. These models were not merely generic tumor proxies but were specifically designed to recapitulate human cancer subtypes, reflecting real-world mutations, histological characteristics, and responses to existing therapies. This careful modeling provides a strong translational bridge between mouse findings and human disease.
The study rigorously confirmed the presence of "cold" and "hot" tumor phenotypes in these models, mirroring observations in human patients and highlighting the challenges in treating immunotherapy-resistant cancers. The unexpected link between tumor hypoxia and elevated EPO levels was a crucial mechanistic insight. Hypoxia is a common feature of aggressive tumors, driving metabolic adaptations and, as now revealed, inadvertently fostering an immunosuppressive microenvironment via EPO. The detailed tracing of the EPO signaling pathway – from tumor cell secretion to macrophage binding and subsequent immunosuppressive reprogramming – provides a comprehensive understanding of how this pathway operates.
The publication in Science, one of the world’s most prestigious scientific journals, attests to the high quality, novelty, and significance of the research. Peer review by leading experts in immunology and oncology has thoroughly scrutinized the methodology and conclusions, ensuring the scientific integrity of the findings. The combinatorial effect observed with anti-PD-1 therapy further validates the potential for synergistic treatments, suggesting that targeting EPO can "prime" resistant tumors for existing immunotherapies. This multi-pronged approach to experimental validation strengthens the conviction that EPO is indeed a central player in cancer immune evasion.
Official Responses and Acknowledgments
The sentiment among the research team is one of profound excitement and optimism. Dr. Engleman’s enthusiasm for the potential translation of these findings into human trials is palpable. Dr. Chiu, as the lead author and a cofounder of ImmunEdge Inc., a pharmaceutical company, brings a unique perspective on the path from basic discovery to therapeutic development. The historical context provided by the FDA’s 2007 black box warning serves not only as a cautionary tale but also as a powerful piece of antecedent evidence that, in retrospect, foreshadowed this groundbreaking discovery.
The research was a collaborative effort, with significant contributions from researchers at the New York Blood Center and ImmunEdge Inc., underscoring the multidisciplinary nature of modern scientific breakthroughs. Financial support for this extensive study was provided by critical grants from the National Institutes of Health (R01CA262361, P01CA244114, U54CA2745115, and P01HL149626), highlighting the importance of federal funding in driving fundamental scientific inquiry.
As is standard journalistic practice, it is important to note the potential conflicts of interest: Dr. Chiu is a cofounder of ImmunEdge Inc., and Dr. Engleman is a founder, shareholder, and board member of the same company. Both researchers are also Stanford-affiliated inventors of PCT/US2023/063997, entitled "EPO receptor agonists and antagonists." These disclosures are crucial for transparency and demonstrate the direct translational interest in bringing these discoveries to clinical application.
Implications: A New Era for Cancer Immunotherapy
The implications of this discovery are far-reaching and hold immense promise for reshaping the landscape of cancer treatment, particularly for those cancers currently resistant to immunotherapy.
Expanding Immunotherapy’s Reach
The most immediate and significant implication is the potential to unlock the power of existing immunotherapies, like anti-PD-1, for a broader range of cancers. Many aggressive cancers – including liver, pancreatic, colorectal, and certain breast and prostate cancers – are characterized by their "cold" immune profiles, making them unresponsive to current checkpoint inhibitors. By converting these cold tumors into hot ones through EPO pathway blockade, this research offers a clear strategy to extend the benefits of immunotherapy to millions more patients.
Novel Therapeutic Strategies
The identification of EPO as a key immunosuppressive molecule opens up several distinct avenues for therapeutic intervention:
-
Non-specific EPO Targeting: One approach could involve therapies that generally lower EPO levels or block its activity. While Dr. Engleman acknowledges that non-specifically targeting EPO could induce anemia, he speculates that this might be an "acceptable trade-off" for an effective cancer therapy, especially for patients facing life-threatening malignancies. The potential for managing anemia with blood transfusions or other supportive care could make this a viable option.
-
Selective EPOR Blockade on Macrophages: A more targeted and potentially less toxic approach would be to selectively block the EPO receptors specifically on the surface of macrophages within the tumor microenvironment. This strategy would aim to reprogram the immunosuppressive macrophages without significantly interfering with systemic EPO’s vital role in red blood cell production, potentially minimizing side effects. This selective targeting could involve antibodies or small molecules designed to specifically interact with macrophage EPORs.
A Paradigm Shift in Understanding Tumor Microenvironment
This discovery represents a fundamental shift in our understanding of the tumor microenvironment. It reveals how a physiological response to hypoxia – the production of EPO to increase oxygen-carrying capacity – can be hijacked by cancer cells to actively suppress the immune system. This intricate interplay highlights the complex evolutionary adaptations that tumors develop to evade host defenses and emphasizes the need for multi-faceted therapeutic approaches that address not only the cancer cells themselves but also their supportive and protective microenvironment.
Broader Applicability Across Cancers
Given the correlation between elevated EPO levels and poorer prognosis observed in human cancers of the kidney, breast, colon, and skin, EPO’s immunosuppressive role is highly likely to extend beyond liver cancer. This suggests that the therapeutic strategies developed from this research could have widespread applicability across numerous cancer types, offering hope for a broad impact on global cancer burden.
Future Research Directions
The current findings pave the way for a flurry of new research. Future efforts will undoubtedly focus on:
- Developing specific inhibitors or antibodies targeting EPO or its receptor on macrophages.
- Conducting preclinical studies to optimize combination therapies, integrating EPO blockade with other immunotherapies, chemotherapy, or radiation.
- Identifying biomarkers that can predict which patients are most likely to benefit from EPO-targeting therapies, potentially through measuring EPO/EPOR levels in tumors or blood.
- Further dissecting the molecular pathways within macrophages that are activated by EPO, to identify even more refined therapeutic targets.
"I continue to be amazed by this finding," Dr. Engleman concluded. "Not every tumor is going to respond in the same way, but I’m very optimistic that this discovery will lead to powerful new cancer therapies." As this promising research moves from the laboratory bench closer to human clinical trials, it carries the profound hope of transforming cold tumors into hot zones of immune activity, offering a new lease on life for countless cancer patients.
About the Author
